218 related articles for article (PubMed ID: 33753747)
1. Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD.
Monteagudo M; Barrecheguren M; Solntseva I; Dhalwani N; Booth A; Nuñez A; Lambrelli D; Miravitlles M
NPJ Prim Care Respir Med; 2021 Mar; 31(1):16. PubMed ID: 33753747
[TBL] [Abstract][Full Text] [Related]
2. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
Wurst KE; Shukla A; Muellerova H; Davis KJ
COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study.
Di Marco F; Santus P; Terraneo S; Peruzzi E; Muscianisi E; Ripellino C; Pegoraro V
NPJ Prim Care Respir Med; 2017 Sep; 27(1):51. PubMed ID: 28883469
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study.
Barrecheguren M; Monteagudo M; Ferrer J; Borrell E; Llor C; Esquinas C; Miravitlles M
Respir Med; 2016 Feb; 111():47-53. PubMed ID: 26758585
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and cost of exacerbations in patients with chronic obstructive pulmonary disease using multiple inhaler triple therapy in South Korea.
Lee CH; Kim MS; Yeo SH; Rhee CK; Park HW; Yang BR; Lee J; Cho EY; Xu X; Navarro Rojas AA; Shantakumar S; Milea D; Choi NK
Respir Res; 2022 Sep; 23(1):231. PubMed ID: 36064539
[TBL] [Abstract][Full Text] [Related]
6. Prescribing pathways to triple therapy in patients with chronic obstructive pulmonary disease in the United States.
Schabert V; Shah S; Holmgren U; Cabrera C
Ther Adv Respir Dis; 2021; 15():17534666211001018. PubMed ID: 33866875
[TBL] [Abstract][Full Text] [Related]
7. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
8. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database.
Calabria S; Ronconi G; Dondi L; Piccinni C; Pedrini A; Esposito I; Pistelli R; Martini N
Pulm Pharmacol Ther; 2020 Apr; 61():101904. PubMed ID: 32092473
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
10. A Real World Study to Assess the Effectiveness of Switching to Once Daily Closed Triple Therapy from Mono/Dual Combination or Open Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.
Huang WC; Chen CY; Liao WC; Wu BR; Chen WC; Tu CY; Chen CH; Cheng WC
Int J Chron Obstruct Pulmon Dis; 2021; 16():1555-1568. PubMed ID: 34113089
[TBL] [Abstract][Full Text] [Related]
11. Differences in Real-World Health and Economic Outcomes Among Patients with COPD Treated with Combination Tiotropium/Olodaterol Versus Triple Therapy.
Palli SR; Frazer M; DuCharme M; Buikema AR; Anderson AJ; Franchino-Elder J
J Manag Care Spec Pharm; 2020 Oct; 26(10):1363-1374. PubMed ID: 32678719
[TBL] [Abstract][Full Text] [Related]
12. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
[TBL] [Abstract][Full Text] [Related]
14. Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain.
Monteagudo M; Nuñez A; Solntseva I; Dhalwani N; Booth A; Barrecheguren M; Lambrelli D; Miravitlles M
Arch Bronconeumol (Engl Ed); 2021 Mar; 57(3):205-213. PubMed ID: 33004238
[TBL] [Abstract][Full Text] [Related]
15. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK.
Brusselle G; Price D; Gruffydd-Jones K; Miravitlles M; Keininger DL; Stewart R; Baldwin M; Jones RC
Int J Chron Obstruct Pulmon Dis; 2015; 10():2207-17. PubMed ID: 26527869
[TBL] [Abstract][Full Text] [Related]
16. Clinical and Economic Impact of Long-Term Inhaled Corticosteroid Withdrawal in Patients with Chronic Obstructive Pulmonary Disease Treated with Triple Therapy in Spain.
Neches García V; Vallejo-Aparicio LA; Ismaila AS; Sicras-Mainar A; Sicras-Navarro A; González C; Cuervo R; Shukla S; García-Peñuela M
Int J Chron Obstruct Pulmon Dis; 2022; 17():2161-2174. PubMed ID: 36101793
[TBL] [Abstract][Full Text] [Related]
17. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.
Chalmers JD; Tebboth A; Gayle A; Ternouth A; Ramscar N
NPJ Prim Care Respir Med; 2017 Jun; 27(1):43. PubMed ID: 28663549
[TBL] [Abstract][Full Text] [Related]
18. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
19. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
